Lumoxiti (Moxetumomab pasudotox) (Moxetumomab pasudotox) — Uses, Dosage, Side Effects & Safety

Drug class: Cancer & Oncology

Overview

Lumoxiti (moxetumomab pasudotox) is a prescription medicine used to treat adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including a purine nucleoside analog. It is not used for other types of leukemia or cancers. Lumoxiti works by targeting the CD22 protein found on the surface of certain cancerous B-cells. It delivers a toxin directly to these cells, leading to their destruction while sparing most healthy cells. This targeted approach helps reduce the number of cancer cells in the body. Key points for patients: Lumoxiti is given as an intravenous infusion by a healthcare professional, typically in a hospital or clinic. It is important to stay hydrated and follow your doctor's instructions closely, as the medication can cause serious side effects such as capillary leak syndrome and kidney problems.

Therapeutic uses

• Hairy cell leukemia (HCL)
• Relapsed or refractory hairy cell leukemia (HCL)

For related Lumoxiti (Moxetumomab pasudotox) guidance, compare Mercaptopurine (6-MP), Kyprolis (Carfilzomib) and Osimertinib / Osimertinib mesylate.

Common side effects

• Capillary leak syndrome
• Hemolytic uremic syndrome
• Infusion-related reactions
• Nausea
• Fatigue
• Peripheral edema
• Pyrexia
• Hypoalbuminemia

Frequently Asked Questions about Lumoxiti (Moxetumomab pasudotox)

What is Lumoxiti used for?

Lumoxiti is used to treat adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including a purine nucleoside analog.

How does Lumoxiti work?

Lumoxiti targets the CD22 protein on cancerous B-cells, delivering a toxin that destroys these cells while sparing most healthy cells.

What are the most serious side effects of Lumoxiti?

The most serious side effects include capillary leak syndrome, kidney problems, hemolytic uremic syndrome, and severe infusion reactions.

Can Lumoxiti be used in children?

No, the safety and effectiveness of Lumoxiti in children under 18 years have not been established.

How is Lumoxiti administered?

Lumoxiti is given as an intravenous infusion by a healthcare professional, typically over 30 minutes on Days 1, 3, and 5 of a 28-day cycle.

What should I do if I miss a dose?

Contact your healthcare provider immediately to reschedule. Do not attempt to self-administer or make up the dose.

Can I take other medications with Lumoxiti?

Always inform your healthcare provider about all medications and supplements you are taking, as interactions may occur, especially with drugs affecting the kidneys.

Educational information only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.